Identifying Blood Biomarkers for Dementia Using Machine Learning Methods in the Framingham Heart Study
暂无分享,去创建一个
E. Benjamin | R. Vasan | Daniel Levy | A. Beiser | S. Seshadri | J. Himali | C. Satizabal | Honghuang Lin | M. Gonzales | Saptaparni Ghosh | E. McGrath | Honghuang Lin | Emer R. McGrath
[1] E. Ifeachor,et al. Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease. , 2016, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.
[2] Debomoy K Lahiri,et al. Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. , 2016, Current Alzheimer research.
[3] Hongyue Dai,et al. A candidate plasma protein classifier to identify Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[4] K. Anstey,et al. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis , 2016, Journal of Alzheimer's disease : JAD.
[5] Monique Breteler,et al. Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.
[6] Stefan Wagenpfeil,et al. Plasma Proteomics for the Identification of Alzheimer Disease , 2013, Alzheimer disease and associated disorders.
[7] D. Levy,et al. Circulating IGFBP‐2: a novel biomarker for incident dementia , 2019, Annals of clinical and translational neurology.
[8] Guanghua Xiao,et al. Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. , 2014, Journal of Alzheimer's disease : JAD.
[9] Albert Hofman,et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study , 2020, Brain : a journal of neurology.
[10] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[11] Weiling Fu,et al. Serum Protein-Based Profiles as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease , 2017, Molecular Neurobiology.
[12] J. Kramer,et al. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes , 2016, Alzheimer's & dementia.
[13] Constantine Frangakis,et al. Multiple imputation by chained equations: what is it and how does it work? , 2011, International journal of methods in psychiatric research.
[14] K. Blennow,et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status , 2019, JAMA neurology.
[15] R. D'Agostino,et al. New Norms for a New Generation: Cognitive Performance in the Framingham Offspring Cohort , 2004, Experimental aging research.
[16] B. Hyman,et al. Serum cystatin C and the risk of Alzheimer disease in elderly men , 2008, Neurology.
[17] Justyna O. Ekert,et al. TNF alpha inhibitors in Alzheimer's disease: A systematic review , 2018, International journal of geriatric psychiatry.
[18] Magda Tsolaki,et al. Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.
[19] Magda Tsolaki,et al. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort , 2019, Alzheimer's & dementia.
[20] O. Peters,et al. Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease , 2020, Alzheimer disease and associated disorders.
[21] Murray Grossman,et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.
[22] J. Jang,et al. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model , 2020, International journal of molecular sciences.
[23] Hye-Ja Lee,et al. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease , 2014, Experimental Gerontology.
[24] R. Mayeux,et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. , 2010, Archives of neurology.
[25] Dan J Stein,et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.
[26] J. C. BurgesChristopher. A Tutorial on Support Vector Machines for Pattern Recognition , 1998 .
[27] Derick R. Peterson,et al. Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.
[28] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[29] M. Fenech,et al. Homocysteine and Dementia: An International Consensus Statement , 2018, Journal of Alzheimer's disease : JAD.
[30] Camille Carroll,et al. Identification of Optimum Panel of Blood-based Biomarkers for Alzheimer’s Disease Diagnosis Using Machine Learning , 2018, 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[31] Christoph Laske,et al. Identification of a blood-based biomarker panel for classification of Alzheimer's disease. , 2011, The international journal of neuropsychopharmacology.
[32] V. Gudnason,et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals , 2016, Alzheimer's & Dementia.
[33] J. Jia,et al. Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer's disease , 2013, Neuroscience Letters.
[34] Nikhil R. Pal,et al. Identification of a small set of plasma signalling proteins using neural network for prediction of Alzheimer's disease , 2015, Bioinform..
[35] W. Kannel,et al. The Framingham Offspring Study. Design and preliminary data. , 1975, Preventive medicine.
[36] Guanghua Xiao,et al. A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.
[37] P. Allhoff,et al. The Framingham Offspring Study , 1991 .
[38] E. Boerwinkle,et al. Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS) , 2016, Alzheimer's & dementia.
[39] H. Xiong,et al. CCL2 Accelerates Microglia-Mediated Aβ Oligomer Formation and Progression of Neurocognitive Dysfunction , 2009, PloS one.
[40] G. Britton,et al. A blood screening test for Alzheimer's disease , 2016, Alzheimer's & dementia.
[41] R B D'Agostino,et al. Lifetime risk of dementia and Alzheimer's disease , 1997, Neurology.
[42] Ramachandran S Vasan,et al. Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. , 2015, International journal of epidemiology.
[43] C. Rowe,et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease , 2018 .
[44] L. McEvoy,et al. Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. , 2015, Age and ageing.
[45] C. Antunez,et al. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[46] Justin Bedo,et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.
[47] Genetic,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[48] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[49] M. Fornage,et al. Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk , 2021, Nature Aging.
[50] E. Tobinick,et al. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. , 2006, MedGenMed : Medscape general medicine.
[51] M. Fornage,et al. MARKVCID PHASE II: PRIORITIZED CANDIDATE SMALL VESSEL VCID BIOMARKERS SELECTED FOR INDEPENDENT MULTI-SITE TESTING AND VALIDATION , 2018, Alzheimer's & Dementia.
[52] Regina Berretta,et al. Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset , 2012, PloS one.
[53] Georg Kemmler,et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.
[54] Mattias Ohlsson,et al. Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease , 2012, PloS one.
[55] K. Yaffe,et al. Leptin, mild cognitive impairment, and dementia among elderly women. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.